417 related articles for article (PubMed ID: 18287589)
1. Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease.
Hennekens CH; Borzak S
J Cardiovasc Pharmacol Ther; 2008 Mar; 13(1):41-50. PubMed ID: 18287589
[TBL] [Abstract][Full Text] [Related]
2. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
[TBL] [Abstract][Full Text] [Related]
4. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
Hermann M; Ruschitzka F
Intern Med J; 2006 May; 36(5):308-19. PubMed ID: 16650196
[TBL] [Abstract][Full Text] [Related]
5. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM
Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 inhibitors and cardiovascular risk.
Solomon SD
Curr Opin Cardiol; 2006 Nov; 21(6):613-7. PubMed ID: 17053413
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
Joshi GP; Gertler R; Fricker R
Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
Vardeny O; Solomon SD
Cardiol Clin; 2008 Nov; 26(4):589-601. PubMed ID: 18929233
[TBL] [Abstract][Full Text] [Related]
10. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?
van Staa TP; Rietbrock S; Setakis E; Leufkens HG
J Intern Med; 2008 Nov; 264(5):481-92. PubMed ID: 18624902
[TBL] [Abstract][Full Text] [Related]
11. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
[TBL] [Abstract][Full Text] [Related]
12. NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac.
Prescrire Int; 2016 Jan; 25(167):14-6. PubMed ID: 26942254
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects of cyclooxygenase-2 inhibitors.
Brophy JM
Curr Opin Gastroenterol; 2007 Nov; 23(6):617-24. PubMed ID: 17906437
[TBL] [Abstract][Full Text] [Related]
14. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications.
Velentgas P; West W; Cannuscio CC; Watson DJ; Walker AM
Pharmacoepidemiol Drug Saf; 2006 Sep; 15(9):641-52. PubMed ID: 16392153
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
Hermann M; Ruschitzka F
Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
McGettigan P; Henry D
JAMA; 2006 Oct; 296(13):1633-44. PubMed ID: 16968831
[TBL] [Abstract][Full Text] [Related]
18. [Overestimated].
Höer A; Häussler B
Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
[No Abstract] [Full Text] [Related]
19. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
; Bhala N; Emberson J; Merhi A; Abramson S; Arber N; Baron JA; Bombardier C; Cannon C; Farkouh ME; FitzGerald GA; Goss P; Halls H; Hawk E; Hawkey C; Hennekens C; Hochberg M; Holland LE; Kearney PM; Laine L; Lanas A; Lance P; Laupacis A; Oates J; Patrono C; Schnitzer TJ; Solomon S; Tugwell P; Wilson K; Wittes J; Baigent C
Lancet; 2013 Aug; 382(9894):769-79. PubMed ID: 23726390
[TBL] [Abstract][Full Text] [Related]
20. Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs.
Maillard M; Burnier M
Expert Opin Drug Saf; 2006 Jan; 5(1):83-94. PubMed ID: 16370958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
